John L. Daristotle

John L. Daristotle

Auto-generated profile, based on publicly available information

John L. Daristotle

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
JDJohn L. Daristotle
John L. Daristotle
ABAdam M. Behrens
Adam M. Behrens
ASAnthony D. Sandler
Anthony D. Sandler
PKPeter Kofinas
Peter Kofinas

24 April 2023 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
ASAurélien Vander Straeten
Aurélien Vander Straeten
MSMorteza Sarmadi
Morteza Sarmadi
JDJohn L. Daristotle
John L. Daristotle
MKMaria Kanelli
Maria Kanelli
LTLisa H. Tostanoski
Lisa H. Tostanoski
AJAna Jaklenec
Ana Jaklenec

24 February 2025 in Nature Materials
Verified
Journal Article
Open access
PDF file
JHJooli Han
Jooli Han
MKMaria Kanelli
Maria Kanelli
YLYang Liu
Yang Liu
JDJohn L. Daristotle
John L. Daristotle
APApurva Pardeshi
Apurva Pardeshi
AJAna Jaklenec
Ana Jaklenec
Medical interventions often require timed series of doses, thus necessitating accurate medical record-keeping. In many global settings, these records are unreliable or unavailable at the point of care, leading to less effective treatments or disease prevention. Here we present an invisible-to-the-naked-eye on-patient medical record-keeping technology that accurately stores medical information in the patient skin as part of microneedles that are used for intradermal therapeutics. We optimize the microneedle design for both a reliable delivery of messenger RNA (mRNA) therapeutics and the near-infrared fluorescent microparticles that encode the on-patient medical record-keeping. Deep learning-based image processing enables encoding and decoding of the information with excellent temporal and spatial robustness. Long-term studies in a swine model demonstrate the safety, efficacy and reliability of this approach for the co-delivery of on-patient medical record-keeping and the mRNA vaccine encoding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This technology could help healthcare workers make informed decisions in circumstances where reliable record-keeping is unavailable, thus contributing to global healthcare equity.

15 July 2022 in Science Advances
Verified
Journal Article
Open access
MSMorteza Sarmadi
Morteza Sarmadi
CTChristina Ta
Christina Ta
AVAbigail M. VanLonkhuyzen
Abigail M. VanLonkhuyzen
DFDominique C. De Fiesta
Dominique C. De Fiesta
MKMaria Kanelli
Maria Kanelli
AJAna Jaklenec
Ana Jaklenec
Next-generation therapeutics require advanced drug delivery platforms with precise control over morphology and release kinetics. A recently developed microfabrication technique enables fabrication of a new class of injectable microparticles with a hollow core-shell structure that displays pulsatile release kinetics, providing such capabilities. Here, we study this technology and the resulting core-shell microstructures. We demonstrated that pulsatile release is governed by a sudden increase in porosity of the polymeric matrix, leading to the formation of a porous path connecting the core to the environment. Moreover, the release kinetics within the range studied remained primarily independent of the particle geometry but highly dependent on its composition. A qualitative technique was developed to study the pattern of pH evolution in the particles. A computational model successfully modeled deformations, indicating sudden expansion of the particle before onset of release. Results of this study contribute to the understanding and design of advanced drug delivery systems.

29 July 2021 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
JDJohn L. Daristotle
John L. Daristotle
MEMetecan Erdi
Metecan Erdi
LLLung W. Lau
Lung W. Lau
SZShadden T. Zaki
Shadden T. Zaki
PSPriya Srinivasan
Priya Srinivasan
PKPeter Kofinas
Peter Kofinas

8 March 2024 in Science Advances
Verified
Journal Article
Open access
SAShahad K. Alsaiari
Shahad K. Alsaiari
SNSeba Nadeef
Seba Nadeef
JDJohn L. Daristotle
John L. Daristotle
WRWilliam Rothwell
William Rothwell
BDBujie Du
Bujie Du
AJAna Jaklenec
Ana Jaklenec
Nanomaterials offer unique opportunities to engineer immunomodulatory activity. In this work, we report the Toll-like receptor agonist activity of a nanoscale adjuvant zeolitic imidazolate framework–8 (ZIF-8). The accumulation of ZIF-8 in endosomes and the pH-responsive release of its subunits enable selective engagement with endosomal Toll-like receptors, minimizing the risk of off-target activation. The intrinsic adjuvant properties of ZIF-8, along with the efficient delivery and biomimetic presentation of a severe acute respiratory syndrome coronavirus 2 spike protein receptor-binding domain trimer, primed rapid humoral and cell-mediated immunity in a dose-sparing manner. Our study offers insights for next-generation adjuvants that can potentially impact future vaccine development.